Connect your AI

BioLife Solutions BLFS Stock-Based Comp

Stock-Based Comp at other companies

Thermo Fisher ScientificTMO

$83M+10.7%

DanaherDHR

$58M-4.9%

AzentaAZTA

$6.36M-23.7%

LeMaitre VascularLMAT

$2.09M+2.2%

TEC

Bio-TechneTECH

$10.5M-7.9%

CryoPort, Inc.CYRX

$2.4M-35.3%

Other financials

Income statement

Revenue$27.5M+24.7%

Gross profit$17.5M+18.2%

Operating income$27.0K+105%

Net income$1.2M+365%

EPS (diluted)$0.02—

Balance sheet

Cash & equivalents$22.8M-65.9%

Total debt$17.4M-35.6%

Total equity$372.2M+5.6%

Total assets$400.9M+1.5%

Cash flow

Operating cash flow-$491.0K-128%

CapEx$167.0K-4.6%

Free cash flow-$658.0K-142%

Valuation

Market cap$1.25B+33.1%

Enterprise value$1.24B+38.1%

P/S12.5×+0.5×

Profitability

Gross margin66.9%—

Operating margin-16.7%—

Net margin-68.7%—

FCF margin-15.9%+18.7pp

Returns & leverage

Return on equity-14.5%-4.7pp

Debt / equity0×0.0×

Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioLife Solutions's stock-based comp?: BioLife Solutions (BLFS) reported stock-based comp of $4.81M in Q1 2026.
How has BioLife Solutions's stock-based comp changed year-over-year?: BioLife Solutions's stock-based comp increased by 15.7% year-over-year, from $4.15M to $4.81M.
What is the long-term trend for BioLife Solutions's stock-based comp?: Over 4 years (2021 to 2025), BioLife Solutions's stock-based comp has grown at a 13.3% compound annual growth rate (CAGR), from $13.96M to $22.99M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.